Developer docs
API playgroundTry for free, no card

Search company profiles

OptraScan

Full company profile

uuid00004ej

Namestring
OptraScan
Legal namestring
OptraSCAN USA, Inc.
Websiteurl
optrascan.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

OptraScan (legal entity OptraSCAN USA, Inc., founded 2015–2016, headquartered in San Jose, CA with an engineering and product development office in Pune, India) is a private digital pathology company that designs and manufactures whole-slide scanners and the surrounding AI-driven image management, telepathology, and disease-specific analysis software. The company's core technical asset is OS-SiA, a US-patented Simultaneous Scan-Index-Analyze technology that performs real-time AI inference during slide acquisition rather than as a post-processing step; this is paired with a separately patented composite imaging method for extended depth of field. The scanner portfolio spans the compact 6-slide OS-SiX, the 15-slide OS-Lite, the high-capacity 80–480-slide OS-Ultra, the dual-mode brightfield/fluorescence OS-FLi, and the intraoperative OS-FS frozen section system. On top of the hardware layer, IMAGEPath provides HIPAA-compliant image management and HL7/API integration to LIS, PACS, LIMS, and HIS systems, while TELEPath enables remote pathologist consultation. Disease-specific AI applications include BactoSiA (TB smear microscopy aligned with WHO grading), CytoSiA (cervical cancer Bethesda classification), HistoSiA Breast (HER2, ER, PR, Ki-67, AE1/3 with Allred/H-Score/ASCO-CAP outputs), plus algorithms for lung PD-L1 (published in Nature), prostate Gleason grading, and Virtual IHC staining.

The business model combines scanner hardware sales (with bundled first-year software licenses) and three software/AI monetization paths: annual subscriptions for IMAGEPath and TELEPath, pay-per-use AI pricing (notably HistoSiA Breast), and per-slide/per-case AI analysis fees. Go-to-market is primarily direct enterprise field sales organized regionally across USA, MEA, and India, supplemented by technology integration partnerships (Paige, Lumea, Karkinos Healthcare), NGO and public-health program channels for screening deployments, and — following Molbio Diagnostics' ~$30M majority-stake acquisition in November 2024 — Molbio's distribution network, particularly in India and global health markets. The platform is certified to ISO 13485:2016, CE-IVDR (EU 2017/746), and CDSCO (India), with HIPAA-compliant cloud and 21 CFR Part 11 software compliance. Customer base spans 46+ disclosed logos across hospital pathology labs, pharmaceutical/CRO research, national screening programs, medical education, and mobile/NGO units, including DBT-validated deployments across 9 hospitals and 10,000 patients in India.

Short descriptiontext

OptraScan (OptraSCAN USA, Inc.) builds AI-enabled whole-slide scanners and digital pathology software — IMAGEPath image management, TELEPath telepathology, and disease-specific AI for TB, cervical, breast, lung, and prostate cancer — sold to hospital pathology labs, pharma/CROs, public-health screening programs, and academic institutions globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Jose, United States
HQ citystring
San Jose
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology, whole slide imaging, pathology imaging scanners, telepathology platforms, cancer biomarker analysis
Industry5 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Optical Instruments & Lenses3827
  • Laboratory Analytical Instruments3826
Product category
Digital Pathology Systems
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Whole Slide Scanner Hardware Sales
TypeHardware Sales
Description

Sale of digital pathology scanners (OS-SiX, OS-Lite, OS-Ultra, OS-FLi). Hardware is sold with bundled software licenses (1-year IMAGEPath license). Pricing models include purchase and leasing options. Scanners range from compact 6-slide capacity to high-throughput 480-slide systems.

optrascan.com
2Software Subscriptions and Licenses
TypeSubscription Recurring
Description

Recurring revenue from IMAGEPath image management software licenses, TELEPath telepathology platform, and AI analytics modules. Software is offered as cloud-based or on-premise solutions with annual subscription billing.

optrascan.com
3Pay-Per-Use / On-Demand Solutions
TypeUsage Based
Description

On-Demand Digital Pathology model allowing customers to pay only for what they use. HistoSiA Breast specifically launched on pay-per-use model. Enables flexible adoption with minimum upfront investment, targeting labs of all sizes and resource-limited settings.

einpresswire.com
4AI-Assisted Diagnostic Solutions
TypeSubscription Recurring
Description

AI-powered analysis solutions including BactoSiA (TB), CytoSiA (cervical cancer), HistoSiA (breast cancer), and cancer biomarker analysis algorithms. Revenue from per-slide or per-case analysis fees, or bundled with scanner/software purchases.

einpresswire.com
5Professional Services and Support
TypeProfessional Services
Description

Technical support services including 24x7 global technical support, installation, training, and on-site maintenance. Professional services for implementation, integration with LIS/PACS systems, and regulatory compliance support.

optrascan.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details4 tiers
1On-Demand / Pay-Per-Use Model
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Customers pay only for what they use with minimum upfront investment. Designed for labs with variable volumes or limited capital budgets. Flexible and scalable based on actual usage.

optrascan.com
2Subscription / Annual Licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Annual software licenses for IMAGEPath, TELEPath, and AI analytics modules. Includes bundled support and updates. Cloud or on-premise deployment options.

optrascan.com
3One-Time Purchase / Perpetual License
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Scanner hardware sold with bundled first-year software license. Leasing options also available for capital-constrained customers.

optrascan.com
4HistoSiA Breast Pay-Per-Use
ModelUsage-basedBilling cadencePay-as-you-go
Notes

AI-enabled HER2 categorization and breast cancer biomarker analysis on a pay-per-use basis, allowing laboratories to shift manual analytical tasks to automation without large upfront cost.

einpresswire.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1BactoSiA
Description

AI-assisted tuberculosis treatment monitoring solution that digitizes and standardizes sputum smear microscopy workflows using high-resolution whole-slide imaging and AI algorithms.

optrascan.com
+7 more records
Core offering1 text field

OptraScan develops and sells whole-slide imaging scanners, AI-driven pathology analytics software, and cloud-enabled image management and telepathology platforms. Its core differentiator is the patented OS-SiA technology, which simultaneously scans, indexes, and performs AI analysis on tissue slides in a single step during image acquisition, reducing diagnostic turnaround time from hours to minutes. The integrated portfolio spans hardware scanners, AI disease-specific solutions (BactoSiA for TB, CytoSiA for cervical cancer, HistoSiA Breast for breast cancer biomarkers), the IMAGEPath workflow platform, and TELEPath remote consultation tools, sold to pathology laboratories, hospitals, pharma, and public health programs worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Reduces diagnostic turnaround time from hours to minutes through real-time simultaneous scan-index-analyze
+6 more records
Product overview1 text field

OptraScan offers an integrated digital pathology ecosystem combining whole slide scanners (OS-SiX, OS-Lite, OS-Ultra, OS-FLi) with AI-powered software platforms and analysis solutions. The core of the portfolio is the patented OS-SiA technology, which enables simultaneous scanning, indexing, and real-time AI analysis during slide acquisition — reducing diagnostic turnaround time from hours to minutes. This technology powers specialized AI solutions including BactoSiA for tuberculosis detection, CytoSiA for cervical cancer screening, and HistoSiA Breast for breast cancer biomarker analysis. The IMAGEPath platform provides HIPAA-compliant image management and archival, while TELEPath enables telepathology consultations. The portfolio also includes standalone cancer analysis modules for breast, cervical, lung, and prostate cancer, plus Virtual IHC staining for reagent-free biomarker visualization, all supported by a cloud-based E-Learning pathology education platform.

Product and service17 records
1OS-SiX Whole Slide Scanner
CategoryWhole slide scanner hardware
Description

Compact 6-slide brightfield whole-slide scanner with integrated AI-powered scanning, indexing, and analysis via OS-SiA technology. Scans 6 standard slides or 3 mega slides in 120 seconds at 20x and 240 seconds at 40x. Designed for low-to-mid-volume pathology labs with limited space.

2OS-Lite Whole Slide Scanner
CategoryWhole slide scanner hardware
Description

15-slide brightfield whole-slide scanner with automated tissue detection and cloud-enabled image management. Scans a 15x15mm area in 40 seconds at 20x or 90 seconds at 40x, with patented composite imaging for extended depth of field.

3OS-Ultra Whole Slide Scanner
CategoryWhole slide scanner hardware
Description

High-capacity brightfield whole-slide scanner with 80 to 480 slide capacity and sub-minute scanning speeds. Features no-touch and continuous slide loading for high-throughput environments, with 0.25 microns per pixel resolution and embedded IMAGEPath/TELEPath software.

4OS-FLi Fluorescence and Brightfield Scanner
CategoryWhole slide scanner hardware
Description

Dual-purpose fluorescence and brightfield whole-slide scanner combining high-resolution fluorescence and brightfield imaging in a single platform. Supports multichannel fluorescence for FISH analysis, IHC quantification, high-content screening, and biomarker discovery.

5OS-FS Frozen Section Imaging
CategoryWhole slide scanner hardware
Description

Real-time frozen section imaging modality for intraoperative pathology review. Features Live View Mode for instant digital microscopy without archived whole-slide imaging, supporting 7-slide frozen or 15-slide FFPE cartridge options. Integrates with IMAGEPath and TELEPath.

6OS-SiA Patented AI Technology Platform
CategoryAI pathology platform
Description

World's first patented AI-powered digital pathology technology that scans, indexes, and analyzes tissue simultaneously during slide acquisition. Transforms scanners from passive image-capture devices into active diagnostic systems, performing on-device AI analytics and reducing diagnostic turnaround from hours to minutes.

7BactoSiA AI Tuberculosis Solution
CategoryAI disease-specific analytics
Description

AI-assisted tuberculosis treatment monitoring solution that digitizes sputum smear microscopy and automatically detects and grades acid-fast bacilli using WHO-aligned standardized criteria (Scanty, 1+, 2+, 3+). Targets public health labs, TB labs, mobile units, and telepathology networks.

8CytoSiA Digital Cytology Platform
CategoryAI disease-specific analytics
Description

AI-powered digital cytology platform for cervical cancer screening. Triages normal and abnormal cases, classifies atypical cells into Bethesda categories (HSIL, LSIL, ASCUS, ASC-H), and generates structured clinician-ready reports. Designed for national cervical screening programs and mid-to-high-volume cytology labs.

9HistoSiA Breast Cancer AI Suite
CategoryAI disease-specific analytics
Description

AI-enabled breast cancer biomarker analysis suite that performs automated HER2 categorization (0, 1+, 2+, 3+) during slide scanning and supports IHC analysis for HER2, ER, PR, Ki-67, and AE1/3 biomarkers. Includes Allred, H-Score, ASCO-CAP, and TNM staging tools. Available on a pay-per-use pricing model.

10Breast Cancer Analysis Algorithm
CategoryAI disease-specific analytics
Description

Digital pathology algorithm for identifying and quantifying breast cancer tumor characteristics including tissue area, tumor area, DCIS, and invasive carcinoma. Supports biomarker evaluation for ER, PR, HER2Neu, Ki67, and P53. Validated across 9 hospitals and 10,000 patients, certified by India's DBT.

11Cervical Cancer Analysis Algorithm
CategoryAI disease-specific analytics
Description

AI-powered machine learning algorithm for identifying precancerous lesions and cancerous cells in cervical cytology samples. Distinguishes normal from abnormal cells and classifies atypical cells into Bethesda categories (HSIL, LSIL, ASCUS, ASC-H), generating Bethesda-format reports.

12Lung Cancer PD-L1 Analysis Algorithm
CategoryAI disease-specific analytics
Description

Automated PD-L1 lung cancer algorithm evaluating PD-L1 expression in tumor and immune cells. Detects partial and complete membrane staining on tumor cells and membrane/cytoplasmic staining on immune cells, generating PD-L1 scores relative to total tumor cells. Validates at least 100 viable tumor cells per sample. Research published in Nature.

13Prostate Cancer Gleason Analysis Algorithm
CategoryAI disease-specific analytics
Description

AI-driven prostate cancer biomarker analysis algorithm with deep learning-based Gleason grading on H&E-stained digital slides. Provides consistent Gleason grade classification for prognostication and treatment planning, with evaluation of key prostate cancer biomarkers.

14Virtual IHC Staining
CategoryAI disease-specific analytics
Description

AI-driven virtual immunohistochemistry staining technology that digitally transforms H&E-stained slides into high-fidelity IHC-equivalent images without physical staining. Eliminates need for chemical reagents, enables multiplex biomarker analysis on a single section, and provides standardized reproducible results.

15IMAGEPath Image Management System
CategoryPathology software platform
Description

Digital pathology image management and workflow software for organizing, viewing, sharing, and archiving whole-slide images. Supports HIPAA-compliant cloud and local storage up to 10TB, interactive viewing with annotation and measurement, side-by-side comparison, role-based access, audit trails, and HL7/API integration with LIS, PACS, LIMS, and HIS.

16TELEPath Telepathology Platform
CategoryPathology software platform
Description

Telepathology software platform for real-time remote consultation and collaboration among pathologists. Facilitates remote sharing and viewing of digital slide images for consultations, second opinions, and multidisciplinary team meetings with live chat and conferencing.

17Pathology E-Learning Platform
CategoryPathology software platform
Description

Cloud-based digital pathology education platform consolidating whole-slide images, course materials, assignments, and assessments. Supports teacher workflows (course creation, slide upload, annotation, live teleconsultation) and student workflows (WSI exploration, annotation review, assignment completion). Includes role-based access and performance tracking dashboards.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Philips offers IntelliSite digital pathology scanners and enterprise pathology workflow software as part of a broad hospital IT and diagnostic imaging portfolio. Directly competes with OptraScan in whole slide imaging and image management for large hospital systems.

TypeBroad incumbent
Description

Leica Biosystems (owned by Danaher) provides Aperio whole slide scanners and pathology workflow software with broad installed base globally. Directly competes with OptraScan's OS-Ultra and IMAGEPath offerings across clinical pathology labs.

TypeDirect peer
Description

Hamamatsu's NanoZoomer is one of the most widely deployed whole slide scanner families globally, including fluorescence and brightfield models. Closely comparable to OptraScan's OS-SiX, OS-Lite, OS-Ultra, and OS-FLi scanner portfolio targeting clinical and research pathology labs.

TypeDirect peer
Description

3DHistech provides PANNORAMIC whole slide scanners, digital pathology workflow software, and AI applications across clinical and research markets. Directly competes with OptraScan across scanner hardware, image management, and AI analytics for pathology.

TypeBroad incumbent
Description

Roche's Ventana slide scanning and digital pathology solutions are bundled with its dominant IHC and companion diagnostics franchise. Competes with OptraScan in integrated hardware-software-AI workflows for hospital pathology labs, especially in oncology.

TypeEmerging player
Description

Paige develops AI-only clinical decision support for pathology, including FDA-authorized prostate and breast cancer applications. Has an explicit partnership with OptraScan, but as an AI-native player Paige could also be seen as an emerging alternative to OptraScan's own AI modules.

TypeDirect peer
Description

Sakura Finetek provides digital pathology and histology workflow solutions including scanners and tissue processing equipment. Overlaps with OptraScan's OS scanner line and broader digital pathology workflow for clinical and research labs.

TypeDirect peer
Description

Huron offers whole slide scanners (TissueScope) and image management software targeted at clinical and research pathology. A comparable mid-market scanner + software peer to OptraScan's OS-SiX/Lite/Ultra and IMAGEPath stack.

TypeEmerging player
Description

Ibex develops AI-powered cancer diagnostics for pathology, including breast and prostate applications with CE marks and Galen platform. An AI-native emerging player whose modules can substitute for some of OptraScan's cancer analysis algorithms.

TypeDirect peer
Description

Motic provides EasyScan and other whole slide scanners with integrated software for clinical, veterinary, and education markets. Competes with OptraScan's compact OS-SiX and OS-Lite scanners in mid-volume and education-focused pathology labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature13 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OptraScan

Digital Pathology Systemsoptrascan.com

OptraScan (OptraSCAN USA, Inc.) builds AI-enabled whole-slide scanners and digital pathology software — IMAGEPath image management, TELEPath telepathology, and disease-specific AI for TB, cervical, breast, lung, and prostate cancer — sold to hospital pathology labs, pharma/CROs, public-health screening programs, and academic institutions globally.

What OptraScan does

OptraScan (legal entity OptraSCAN USA, Inc., founded 2015–2016, headquartered in San Jose, CA with an engineering and product development office in Pune, India) is a private digital pathology company that designs and manufactures whole-slide scanners and the surrounding AI-driven image management, telepathology, and disease-specific analysis software. The company's core technical asset is OS-SiA, a US-patented Simultaneous Scan-Index-Analyze technology that performs real-time AI inference during slide acquisition rather than as a post-processing step; this is paired with a separately patented composite imaging method for extended depth of field. The scanner portfolio spans the compact 6-slide OS-SiX, the 15-slide OS-Lite, the high-capacity 80–480-slide OS-Ultra, the dual-mode brightfield/fluorescence OS-FLi, and the intraoperative OS-FS frozen section system. On top of the hardware layer, IMAGEPath provides HIPAA-compliant image management and HL7/API integration to LIS, PACS, LIMS, and HIS systems, while TELEPath enables remote pathologist consultation. Disease-specific AI applications include BactoSiA (TB smear microscopy aligned with WHO grading), CytoSiA (cervical cancer Bethesda classification), HistoSiA Breast (HER2, ER, PR, Ki-67, AE1/3 with Allred/H-Score/ASCO-CAP outputs), plus algorithms for lung PD-L1 (published in Nature), prostate Gleason grading, and Virtual IHC staining.

The business model combines scanner hardware sales (with bundled first-year software licenses) and three software/AI monetization paths: annual subscriptions for IMAGEPath and TELEPath, pay-per-use AI pricing (notably HistoSiA Breast), and per-slide/per-case AI analysis fees. Go-to-market is primarily direct enterprise field sales organized regionally across USA, MEA, and India, supplemented by technology integration partnerships (Paige, Lumea, Karkinos Healthcare), NGO and public-health program channels for screening deployments, and — following Molbio Diagnostics' ~$30M majority-stake acquisition in November 2024 — Molbio's distribution network, particularly in India and global health markets. The platform is certified to ISO 13485:2016, CE-IVDR (EU 2017/746), and CDSCO (India), with HIPAA-compliant cloud and 21 CFR Part 11 software compliance. Customer base spans 46+ disclosed logos across hospital pathology labs, pharmaceutical/CRO research, national screening programs, medical education, and mobile/NGO units, including DBT-validated deployments across 9 hospitals and 10,000 patients in India.

OptraScan firmographics

Firmographics
Name
OptraScan
Legal name
OptraSCAN USA, Inc.
Website
https://optrascan.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
OptraScan (OptraSCAN USA, Inc.) builds AI-enabled whole-slide scanners and digital pathology software — IMAGEPath image management, TELEPath telepathology, and disease-specific AI for TB, cervical, breast, lung, and prostate cancer — sold to hospital pathology labs, pharma/CROs, public-health screening programs, and academic institutions globally.
Ownership category
akta.pro rank

OptraScan industry classification

Industry
Product category
Digital Pathology Systems
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Digital pathology
  • Whole slide imaging
  • Pathology imaging scanners
  • Telepathology platforms
  • Cancer biomarker analysis

Where OptraScan is headquartered

Location

Headquarters

HQ city
San Jose
HQ country
United States
HQ region
North America

Offices2 records

Markets served

OptraScan business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Whole Slide Scanner Hardware Sales: Sale of digital pathology scanners (OS-SiX, OS-Lite, OS-Ultra, OS-FLi). Hardware is sold with bundled software licenses (1-year IMAGEPath license). Pricing models include purchase and leasing options. Scanners range from compact 6-slide capacity to high-throughput 480-slide systems.
  2. Software Subscriptions and Licenses: Recurring revenue from IMAGEPath image management software licenses, TELEPath telepathology platform, and AI analytics modules. Software is offered as cloud-based or on-premise solutions with annual subscription billing.
  3. Pay-Per-Use / On-Demand Solutions: On-Demand Digital Pathology model allowing customers to pay only for what they use. HistoSiA Breast specifically launched on pay-per-use model. Enables flexible adoption with minimum upfront investment, targeting labs of all sizes and resource-limited settings.
  4. AI-Assisted Diagnostic Solutions: AI-powered analysis solutions including BactoSiA (TB), CytoSiA (cervical cancer), HistoSiA (breast cancer), and cancer biomarker analysis algorithms. Revenue from per-slide or per-case analysis fees, or bundled with scanner/software purchases.
  5. Professional Services and Support: Technical support services including 24x7 global technical support, installation, training, and on-site maintenance. Professional services for implementation, integration with LIS/PACS systems, and regulatory compliance support.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goOn-Demand / Pay-Per-Use Model
SubscriptionAnnualSubscription / Annual Licensing
One time/ perpetual licenseMulti-year contractOne-Time Purchase / Perpetual License
Usage-basedPay-as-you-goHistoSiA Breast Pay-Per-Use

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

OptraScan product offering

Product offering

Core offering

OptraScan develops and sells whole-slide imaging scanners, AI-driven pathology analytics software, and cloud-enabled image management and telepathology platforms. Its core differentiator is the patented OS-SiA technology, which simultaneously scans, indexes, and performs AI analysis on tissue slides in a single step during image acquisition, reducing diagnostic turnaround time from hours to minutes. The integrated portfolio spans hardware scanners, AI disease-specific solutions (BactoSiA for TB, CytoSiA for cervical cancer, HistoSiA Breast for breast cancer biomarkers), the IMAGEPath workflow platform, and TELEPath remote consultation tools, sold to pathology laboratories, hospitals, pharma, and public health programs worldwide.

Product overview

OptraScan offers an integrated digital pathology ecosystem combining whole slide scanners (OS-SiX, OS-Lite, OS-Ultra, OS-FLi) with AI-powered software platforms and analysis solutions. The core of the portfolio is the patented OS-SiA technology, which enables simultaneous scanning, indexing, and real-time AI analysis during slide acquisition — reducing diagnostic turnaround time from hours to minutes. This technology powers specialized AI solutions including BactoSiA for tuberculosis detection, CytoSiA for cervical cancer screening, and HistoSiA Breast for breast cancer biomarker analysis. The IMAGEPath platform provides HIPAA-compliant image management and archival, while TELEPath enables telepathology consultations. The portfolio also includes standalone cancer analysis modules for breast, cervical, lung, and prostate cancer, plus Virtual IHC staining for reagent-free biomarker visualization, all supported by a cloud-based E-Learning pathology education platform.

Differentiator

Problem solved

Functional benefit

Brands

  • BactoSiA: AI-assisted tuberculosis treatment monitoring solution that digitizes and standardizes sputum smear microscopy workflows using high-resolution whole-slide imaging and AI algorithms.
  • CytoSiA
  • HistoSiA Breast
  • IMAGEPath
  • TELEPath
  • OptraSCAN Pathology E-Learning Platform
  • OS-SiA
  • OS-FS

Products and services

  • OS-SiX Whole Slide Scanner Compact 6-slide brightfield whole-slide scanner with integrated AI-powered scanning, indexing, and analysis via OS-SiA technology. Scans 6 standard slides or 3 mega slides in 120 seconds at 20x and 240 seconds at 40x. Designed for low-to-mid-volume pathology labs with limited space.
  • OS-Lite Whole Slide Scanner 15-slide brightfield whole-slide scanner with automated tissue detection and cloud-enabled image management. Scans a 15x15mm area in 40 seconds at 20x or 90 seconds at 40x, with patented composite imaging for extended depth of field.
  • OS-Ultra Whole Slide Scanner High-capacity brightfield whole-slide scanner with 80 to 480 slide capacity and sub-minute scanning speeds. Features no-touch and continuous slide loading for high-throughput environments, with 0.25 microns per pixel resolution and embedded IMAGEPath/TELEPath software.
  • OS-FLi Fluorescence and Brightfield Scanner Dual-purpose fluorescence and brightfield whole-slide scanner combining high-resolution fluorescence and brightfield imaging in a single platform. Supports multichannel fluorescence for FISH analysis, IHC quantification, high-content screening, and biomarker discovery.
  • OS-FS Frozen Section Imaging Real-time frozen section imaging modality for intraoperative pathology review. Features Live View Mode for instant digital microscopy without archived whole-slide imaging, supporting 7-slide frozen or 15-slide FFPE cartridge options. Integrates with IMAGEPath and TELEPath.
  • OS-SiA Patented AI Technology Platform World's first patented AI-powered digital pathology technology that scans, indexes, and analyzes tissue simultaneously during slide acquisition. Transforms scanners from passive image-capture devices into active diagnostic systems, performing on-device AI analytics and reducing diagnostic turnaround from hours to minutes.
  • BactoSiA AI Tuberculosis Solution AI-assisted tuberculosis treatment monitoring solution that digitizes sputum smear microscopy and automatically detects and grades acid-fast bacilli using WHO-aligned standardized criteria (Scanty, 1+, 2+, 3+). Targets public health labs, TB labs, mobile units, and telepathology networks.
  • CytoSiA Digital Cytology Platform AI-powered digital cytology platform for cervical cancer screening. Triages normal and abnormal cases, classifies atypical cells into Bethesda categories (HSIL, LSIL, ASCUS, ASC-H), and generates structured clinician-ready reports. Designed for national cervical screening programs and mid-to-high-volume cytology labs.
  • HistoSiA Breast Cancer AI Suite AI-enabled breast cancer biomarker analysis suite that performs automated HER2 categorization (0, 1+, 2+, 3+) during slide scanning and supports IHC analysis for HER2, ER, PR, Ki-67, and AE1/3 biomarkers. Includes Allred, H-Score, ASCO-CAP, and TNM staging tools. Available on a pay-per-use pricing model.
  • Breast Cancer Analysis Algorithm Digital pathology algorithm for identifying and quantifying breast cancer tumor characteristics including tissue area, tumor area, DCIS, and invasive carcinoma. Supports biomarker evaluation for ER, PR, HER2Neu, Ki67, and P53. Validated across 9 hospitals and 10,000 patients, certified by India's DBT.
  • Cervical Cancer Analysis Algorithm AI-powered machine learning algorithm for identifying precancerous lesions and cancerous cells in cervical cytology samples. Distinguishes normal from abnormal cells and classifies atypical cells into Bethesda categories (HSIL, LSIL, ASCUS, ASC-H), generating Bethesda-format reports.
  • Lung Cancer PD-L1 Analysis Algorithm Automated PD-L1 lung cancer algorithm evaluating PD-L1 expression in tumor and immune cells. Detects partial and complete membrane staining on tumor cells and membrane/cytoplasmic staining on immune cells, generating PD-L1 scores relative to total tumor cells. Validates at least 100 viable tumor cells per sample. Research published in Nature.
  • Prostate Cancer Gleason Analysis Algorithm AI-driven prostate cancer biomarker analysis algorithm with deep learning-based Gleason grading on H&E-stained digital slides. Provides consistent Gleason grade classification for prognostication and treatment planning, with evaluation of key prostate cancer biomarkers.
  • Virtual IHC Staining AI-driven virtual immunohistochemistry staining technology that digitally transforms H&E-stained slides into high-fidelity IHC-equivalent images without physical staining. Eliminates need for chemical reagents, enables multiplex biomarker analysis on a single section, and provides standardized reproducible results.
  • IMAGEPath Image Management System Digital pathology image management and workflow software for organizing, viewing, sharing, and archiving whole-slide images. Supports HIPAA-compliant cloud and local storage up to 10TB, interactive viewing with annotation and measurement, side-by-side comparison, role-based access, audit trails, and HL7/API integration with LIS, PACS, LIMS, and HIS.
  • TELEPath Telepathology Platform Telepathology software platform for real-time remote consultation and collaboration among pathologists. Facilitates remote sharing and viewing of digital slide images for consultations, second opinions, and multidisciplinary team meetings with live chat and conferencing.
  • Pathology E-Learning Platform Cloud-based digital pathology education platform consolidating whole-slide images, course materials, assignments, and assessments. Supports teacher workflows (course creation, slide upload, annotation, live teleconsultation) and student workflows (WSI exploration, annotation review, assignment completion). Includes role-based access and performance tracking dashboards.

Quantifiable outcome

  • Reduces diagnostic turnaround time from hours to minutes through real-time simultaneous scan-index-analyze
  • +6 more outcomes

Companies that use OptraScan

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

OptraScan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature13 records

OptraScan partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

OptraScan competitors and assessment

Company assessment

Broad incumbents

  • Philips (IntelliSite Pathology): Philips offers IntelliSite digital pathology scanners and enterprise pathology workflow software as part of a broad hospital IT and diagnostic imaging portfolio. Directly competes with OptraScan in whole slide imaging and image management for large hospital systems.
  • Leica Biosystems (Aperio, Danaher): Leica Biosystems (owned by Danaher) provides Aperio whole slide scanners and pathology workflow software with broad installed base globally. Directly competes with OptraScan's OS-Ultra and IMAGEPath offerings across clinical pathology labs.
  • Roche (Ventana DP 200): Roche's Ventana slide scanning and digital pathology solutions are bundled with its dominant IHC and companion diagnostics franchise. Competes with OptraScan in integrated hardware-software-AI workflows for hospital pathology labs, especially in oncology.

Direct peers

  • Hamamatsu Photonics (NanoZoomer): Hamamatsu's NanoZoomer is one of the most widely deployed whole slide scanner families globally, including fluorescence and brightfield models. Closely comparable to OptraScan's OS-SiX, OS-Lite, OS-Ultra, and OS-FLi scanner portfolio targeting clinical and research pathology labs.
  • 3DHistech: 3DHistech provides PANNORAMIC whole slide scanners, digital pathology workflow software, and AI applications across clinical and research markets. Directly competes with OptraScan across scanner hardware, image management, and AI analytics for pathology.
  • Sakura Finetek: Sakura Finetek provides digital pathology and histology workflow solutions including scanners and tissue processing equipment. Overlaps with OptraScan's OS scanner line and broader digital pathology workflow for clinical and research labs.
  • Huron Digital Pathology: Huron offers whole slide scanners (TissueScope) and image management software targeted at clinical and research pathology. A comparable mid-market scanner + software peer to OptraScan's OS-SiX/Lite/Ultra and IMAGEPath stack.
  • Motic Digital Pathology: Motic provides EasyScan and other whole slide scanners with integrated software for clinical, veterinary, and education markets. Competes with OptraScan's compact OS-SiX and OS-Lite scanners in mid-volume and education-focused pathology labs.

Emerging players

  • Paige.AI: Paige develops AI-only clinical decision support for pathology, including FDA-authorized prostate and breast cancer applications. Has an explicit partnership with OptraScan, but as an AI-native player Paige could also be seen as an emerging alternative to OptraScan's own AI modules.
  • Ibex Medical Analytics: Ibex develops AI-powered cancer diagnostics for pathology, including breast and prostate applications with CE marks and Galen platform. An AI-native emerging player whose modules can substitute for some of OptraScan's cancer analysis algorithms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

OptraScan social profiles

Digital presence

OptraScan compliance and trust

Trust signal

Compliance5 records

OptraScan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OptraScan leadership team

Management profile

Number of profiles

Profiles6 records

OptraScan funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OptraScan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OptraScan

What does OptraScan do?

OptraScan develops and sells whole-slide imaging scanners, AI-driven pathology analytics software, and cloud-enabled image management and telepathology platforms. Its core differentiator is the patented OS-SiA technology, which simultaneously scans, indexes, and performs AI analysis on tissue slides in a single step during image acquisition, reducing diagnostic turnaround time from hours to minutes. The integrated portfolio spans hardware scanners, AI disease-specific solutions (BactoSiA for TB, CytoSiA for cervical cancer, HistoSiA Breast for breast cancer biomarkers), the IMAGEPath workflow platform, and TELEPath remote consultation tools, sold to pathology laboratories, hospitals, pharma, and public health programs worldwide.

Is OptraScan a public or private company?

OptraScan is a private company. It is classified as corporate owned and is currently operating.

When was OptraScan founded?

OptraScan was founded in 2016. It employs 51 to 100 people.

Where is OptraScan based?

OptraScan is headquartered in San Jose, United States, in the North America region.

How does OptraScan make money?

Five revenue lines are on record. Whole Slide Scanner Hardware Sales are the primary driver. The others are software Subscriptions and Licenses, pay-Per-Use / On-Demand Solutions, AI-Assisted Diagnostic Solutions and professional Services and Support.

Who are OptraScan's main competitors?

Broad incumbents on record are Philips (IntelliSite Pathology), Leica Biosystems (Aperio, Danaher) and Roche (Ventana DP 200). Direct peers are Hamamatsu Photonics (NanoZoomer), 3DHistech, Sakura Finetek, Huron Digital Pathology and Motic Digital Pathology. Emerging players are Paige.AI and Ibex Medical Analytics.

Does OptraScan have an API?

No public API is recorded for OptraScan.

What industry is OptraScan in?

OptraScan's product category is Digital Pathology Systems. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 3345 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ani NewsOptraSCAN Empowers AIG Hospitals with Digital Pathology SolutionsOptraSCAN has successfully implemented its OS-Ultra high-speed Digital Pathology Platform at AIG Hospitals in Hyderabad, India. This partnership aims to revolutionize diagnostic processes by enabling AI-based analytics, optimizing workflows, and facilitating remote case reviews through digitized pathology solutions.openPR.comArtificial Intelligence (AI) Pathology Quality Control Market Report Examines Leading Companies And Growth OpportunitiesThe Business Research Company released a market report projecting the AI pathology quality control market will grow from $1.78 billion in 2025 to $4.65 billion by 2030 at a CAGR of 21.1%. The report highlights key industry players and specific corporate developments, such as Molbio Diagnostics' acquisition of OptraSCAN Inc., alongside product innovations like PathAI's Artifact Detect 1 tool.Business StandardMolbio eyes overseas growth after OptraScan secures USFDA clearanceMolbio Diagnostics is seeking to expand its overseas business through its US-based digital pathology subsidiary OptraScan, which received USFDA 510(k) clearance in July for its HER2 scoring system used to assess breast cancer biopsy samples. The expansion comes as Molbio prepares for an IPO of up to Rs 200 crore while facing a 29.5 percent decline in overseas revenue to Rs 139.04 crore in FY26, attributed to Gulf logistics disruptions rather than structural demand weakness. Molbio is diversifying from its TB-testing dominated business, where Truenat kits generated 70.20 percent of finished-goods revenue, with plans to extend its multi-disease platform to hepatitis and HPV screening programs.Elets BFSIOptraSCAN Advances Global Expansion with U.S. FDA ClearanceOptraSCAN, a California-headquartered digital pathology company backed by Molbio Diagnostics, has received U.S. FDA 510(k) clearance for its integrated OptraSCAN System, covering the OS-Ultra Whole Slide Scanner, display monitor, workstation with image management software, and HER2 Image Analysis Software for breast cancer diagnosis. The regulatory approval represents a major milestone supporting the company's mission to advance digital pathology globally while strengthening its position as a technology partner for hospitals, diagnostic laboratories, and life sciences organisations. The achievement also highlights the strategic value of Molbio Diagnostics' majority investment in OptraSCAN completed in 2025, advancing the global shift toward AI-enabled digital pathology solutions.www.passionateinmarketing.comOptraSCAN Secures USFDA 510(k) for Digital PathologyOptraSCAN, Inc., a California-based digital pathology company in which Molbio Diagnostics acquired a majority stake in 2025, has received U.S. FDA 510(k) clearance (K260755) for its integrated OptraSCAN System. The cleared system combines the OS-Ultra Whole Slide Scanner, color display monitor, and ImagePath Image Management Software including HER2 Image Analysis Software, enabling pathologists to review and assess HER2 expression for breast cancer characterization and therapeutic decision-making. The FDA clearance represents a significant milestone validating years of product development and strengthening OptraSCAN's position as a technology partner for hospitals, diagnostic laboratories, and life sciences organizations globally.EIN PresswireOptraSCAN System Receives FDA ClearanceOptraSCAN received FDA 510(k) clearance (K260755) for its OptraSCAN System, an integrated platform with the OS-Ultra Scanner and ImagePath software including HER2 image analysis. The clearance supports its pay-per-use Digital Lab as a service model, aiming to make digital pathology affordable and scalable for laboratories of all sizes.The Times of IndiaBoat enters Singapore market, expands partnersship with Flipkart co-founder’s Binny Bansal-backed OpptraBoat has entered the Singapore market, partnering with Opptra to launch its TWS earbuds, headphones, and charging solutions on Shopee, Lazada, and TikTok Shop. The move follows its Malaysia debut and aims to target Singapore's tech-savvy youth with premium audio at accessible prices.EIN PresswireOptraSCAN Launches HistoSiA™ Breast Pay-Per-Use: Scan, Analyze & Auto-Segregate Breast Cancer IHC Cases in One WorkflowOptraSCAN launched HistoSiA Breast, an AI-enabled digital pathology platform that automates breast cancer biomarker analysis, specifically HER2 categorization (0, 1+, 2+, 3+), during slide scanning on a pay-per-use pricing model. The platform combines whole-slide imaging with real-time AI analysis, allowing laboratories to shift manual analytical tasks to automation and enabling pathologists to focus on diagnostic decision-making. OptraSCAN is pursuing regulatory clearance for components of the platform in select markets and will showcase it at the USCAP Annual Meeting in San Antonio, Texas, March 22-25, 2026.PharmiWeb.comOptraSCAN Launches BactoSiA™, Bringing AI-Enabled Standardization to TB Smear MicroscopyOptraSCAN, a digital pathology company and Molbio Group subsidiary, announced the launch of BactoSiA, an AI-assisted tuberculosis treatment monitoring solution that digitizes and standardizes sputum smear microscopy workflows using high-resolution whole-slide imaging and AI algorithms to automatically detect and grade acid-fast bacilli. The solution generates standardized bacillary load grading aligned with international TB reporting guidelines to support treatment monitoring, follow-up, and clinical decision-making across public health labs, mid/high-volume TB labs, mobile units, and telepathology networks. OptraSCAN will officially launch BactoSiA at the WHX Labs World Health Expo in Dubai from February 10-13, 2026, with live demonstrations and a technology presentation by Chief Product Officer Devika Gholap.The Desert SunOptraSCAN® Launches BactoSiA™, Bringing AI-Enabled Standardization to TB Smear MicroscopyOptraSCAN launched BactoSiA™, an AI-enabled TB smear microscopy solution, at the World Health Expo in Dubai. The product automates and standardizes the analysis of sputum samples to improve TB treatment monitoring and reporting.